FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 331:1350-1353 November 17, 1994 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

In today's prescription-drug marketplace a host of similar products compete for essentially the same population of patients. Between 1989 and 1993, for example, the Center for Drug Evaluation and Research of the Food and Drug Administration (FDA) approved 127 new molecular entities (excluding generic drugs), but only a minority offered a clear clinical advantage over existing therapies¹. Many of the others are considered "me too" drugs because they are so similar to brand-name drugs already on the market.

The preponderance of "me too" drugs has created a highly competitive marketplace for prescription drugs. Pharmaceutical companies are waging aggressive campaigns . . . [Full Text of this Article]

Crowded Therapeutic Classes

Seeding Trials

False and Misleading Claims

Switch Campaigns

Conclusions

Source Information

From the Food and Drug Administration, Department of Health and Human Services, Rockville, Md.

Address reprint requests to Ms. Rose at the FDA, Division of Drug Marketing, Advertising, and Communications, HFD-240, 5600 Fishers Ln., Rockville, MD 20857.

References

Related Letters:

Drug Promotion
Hoberman D., Puma J. L., Cohen S. N., Mossinghoff G. J., Stryer D. B., Bero L. A., Kalish R. S., Kessler D. A., Rose J. L., Temple R. J., Schapiro R., Griffin J. P., Stern R. S.
Extract | Full Text  
N Engl J Med 1995; 332:1031-1033, Apr 13, 1995. Correspondence

This article has been cited by other articles:

• Egilman, D. (2009). Just say no. BMJ 339: b4527-b4527 [Full Text]  
• Wynia, M., Boren, D. (2009). Better regulation of industry-sponsored clinical trials is long overdue.. J Law Med Ethics 37: 410-419  
• Nijsten, T., Spuls, P. I., Naldi, L., Stern, R. S. (2009). The Misperception That Clinical Trial Data Reflect Long-term Drug Safety: Lessons Learned From Efalizumab's Withdrawal. Arch Dermatol 145: 1037-1039 [Full Text]  
• Edelman, J. M. (2008). ADVANTAGE: Science First, Marketing Second. ANN INTERN MED 149: 773-773 [Full Text]  
• Hill, K. P., Egilman, D. S., Krumholz, H. M. (2008). ADVANTAGE: Science First, Marketing Second. ANN INTERN MED 149: 773-774 [Full Text]  
• Booth, C. M., Mackillop, W. J. (2008). Translating New Medical Therapies Into Societal Benefit: The Role of Population-Based Outcome Studies. JAMA 300: 2177-2179 [Full Text]  
• Hill, K. P., Ross, J. S., Egilman, D. S., Krumholz, H. M. (2008). The ADVANTAGE Seeding Trial: A Review of Internal Documents. ANN INTERN MED 149: 251-258 [Abstract] [Full Text]  
• Sox, H. C., Rennie, D. (2008). Seeding Trials: Just Say "No". ANN INTERN MED 149: 279-280 [Full Text]  
• Katz, K. A. (2008). Time to Nip "Seeding Trials" in the Bud. Arch Dermatol 144: 403-404 [Full Text]  
• Psaty, B. M., Rennie, D. (2006). Clinical Trial Investigators and Their Prescribing Patterns: Another Dimension to the Relationship Between Physician Investigators and the Pharmaceutical Industry. JAMA 295: 2787-2790 [Full Text]  
• Brodkey, A. C. (2005). The Role of the Pharmaceutical Industry in Teaching Psychopharmacology: A Growing Problem. Acad. Psychiatry 29: 222-229 [Abstract] [Full Text]  
• Kennedy, H. L., Rosenson, R. S. (2002). Physicians' interpretation of "class effects": A need for thoughtful re-evaluation. J Am Coll Cardiol 40: 19-26 [Abstract] [Full Text]  
• Bodenheimer, T. S. (2001). Affordable Prescriptions for the Elderly. JAMA 286: 1762-1763 [Full Text]  
• Mamdani, M. M., Tu, J. V. (2001). Did the major clinical trials of statins affect prescribing behaviour?. CMAJ 164: 1695-1696 [Full Text]  
• Junker, C., Egger, M., Schneider, M., Zellweger, T., Antes, G. (1996). The CONSORT Statement. JAMA 276: 1876-1877 [Abstract]  
• Cohen, J. S., Insel, P. A. (1996). The Physicians' Desk Reference: Problems and Possible Improvements. Arch Intern Med 156: 1375-1380 [Abstract]  
• Coller, B. S. (1995). Blockade of Platelet GPIIb/IIIa Receptors as an Antithrombotic Strategy. Circulation 92: 2373-2380 [Full Text]  
• Hoberman, D., Puma, J. L., Cohen, S. N., Mossinghoff, G. J., Stryer, D. B., Bero, L. A., Kalish, R. S., Kessler, D. A., Rose, J. L., Temple, R. J., Schapiro, R., Griffin, J. P., Stern, R. S. (1995). Drug Promotion. NEJM 332: 1031-1033 [Full Text]